|
| Tuesday, October 16, 2018 |
|
|
Eisai Signs Collaboration Agreement for Anti-Obesity Agent Lorcaserin in Latin America With Eurofarma |
| Under this agreement, Eisai will supply Eurofarma with lorcaserin. Eisai will receive a one-time contractual payment and is eligible for milestone payments for development and sales in each country. more info >> |
|
| Friday, October 12, 2018 |
|
|
Eisai's New Drug Application for Perampanel for Adjunctive Treatment of Partial Onset Seizures Accepted in China |
| This application for perampanel in partial onset seizures in China was based on the results of three Phase III clinical studies conducted mainly in Europe and the United States, as well as the results of a Phase III clinical study (Study 335) conducted mainly in Asia including China and Japan. more info >> |
|
|
エーザイ、抗てんかん剤ペランパネルの中国における部分てんかん併用療法に係る適応の新薬承認申請が受理 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、自社創製の抗てんかん剤ペランパネル（一般名 日本製品名 「フィコンパ(R)」、海外製品名「Fycompa(R)」)について、中国国家薬品監督管理局に、12 歳以上の部分てんかん併用療法に係る適応の新薬承認申請が受理されたことをお知らせします。 more info >> |
|
| Wednesday, October 10, 2018 |
|
|
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO 2018 Congress |
| At the ESMO 2018 Congress, there will be an oral presentation on tumor growth rate prior to treatment administration and efficacy of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer. more info >> |
|
|
欧州臨床腫瘍学会年次総会におけるエーザイのがん領域の開発品・製品に関する演題について |
| エーザイ、欧州臨床腫瘍学会年次総会におけるエーザイのがん領域の開発品・製品に関する演題について more info >> |
|
| Friday, October 5, 2018 |
|
|
エーザイ、肥満症治療剤「BELVIQ」の長期心血管疾患アウトカム試験における2型糖尿病の予防と寛解に関する新しいデータを発表 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、このたび、肥満症治療剤lorcaserin hydrochloride（一般名、米国製品名「BELVIQ(R)」、以下 「BELVIQ」）の長期心血管疾患アウトカム試験（CAMELLIA-TIMI61試験）における、2型糖尿病の予防と寛解に関する新しいデータについて、ドイツ・ベルリンで開催されている第54回欧州糖尿病学会（EASD）年次総会において発表するとともに、世界的に最も権威のある医学雑誌の一つであるThe Lancetに掲載されたことをお知らせします。 more info >> |
|
|
New Data on Effect of Anti-Obesity Agent BELVIQ on Prevention and Remission of Type 2 Diabetes Presented at The European Association for the Study of Diabetes and Published in The Lancet |
| This new analysis assessed metabolic effects on enrolled patients with T2DM or pre-diabetes (higher than normal blood sugar levels prior to incidence of diabetes) at baseline, as well as patients with normoglycemia. more info >> |
|
| Monday, October 1, 2018 |
|
|
エーザイ、抗てんかん剤「Fycompa」が米国FDAより小児てんかんの部分発作に係る承認を新たに取得 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、米国子会社のエーザイ・インクが、自社創製の抗てんかん剤 「Fycompa(R)」（一般名：ペランパネル、 日本製品名「フィコンパ(R)」)について、米国食品医薬品局(FDA)より、4歳以上の小児てんかん患者様の部分発作に係る承認を取得したことをお知らせします。 more info >> |
|
|
Eisai's Fycompa Newly Approved by U.S. FDA as Treatment for Partial-Onset Seizures in Pediatric Patients with Epilepsy |
| Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. received approval from the U.S. FDA for an indication expansion for Eisai's antiepileptic drug (AED) Fycompa (perampanel) to cover partial-onset seizures in pediatric patients with epilepsy 4 years of age and older. Fycompa was designated for Priority Review by the FDA, and was approved approximately six months after submission. more info >> |
|
| Wednesday, September 5, 2018 |
|
|
Eisai And Merck & Co. Announce China NMPA Approval of First Approval for LENVIMA (Lenvatinib) for Treatment of Unresectable HCC |
| Eisai Co., Ltd. and Merck & Co. known as MSD outside of the United States and Canada, announced that the China National Medical Products Administration (NMPA) approved the kinase inhibitor LENVIMA (lenvatinib) as a single agent for the treatment of patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. more info >> |
|
|
|
|
